ArticleBasic & clinical pharmacology & toxicology2025
The Incidence of Benzodiazepine and Benzodiazepine-Related Drug Use in People With and Without Parkinson's Disease-A Nationwide Cohort Study.
Article in Basic & clinical pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sex-specific gray matter underpinnings of anxiety and their mediating mechanisms inFrontiers in aging neuroscience · 2026Article
- The Incidence of Benzodiazepine and Benzodiazepine-Related Drug Use in People With and Without Parkinson's Disease-A Nationwide Cohort Study.Basic & clinical pharmacology & toxicology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-motor symptoms of Parkinson's disease (PD), including sleep problems and anxiety, are common and can appear before motor symptoms. Benzodiazepines and benzodiazepine-related drugs (BZDR) may be used to treat these symptoms, although they are associated with an increased fall risk. It is unknown how the incidence of BZDR use changes in relation to PD diagnosis.
objectiveTo investigate the incidence of BZDR use in people with and without PD from 6 years before to 10 years after the PD diagnosis.
methodsA nationwide register-based FINPARK cohort includes 18 651 persons diagnosed with PD in 1996-2015 and their matched comparison persons (n = 127 806). BZDR incidence was ascertained from a national prescription register. The study adheres to RECORD-PE reporting guideline.
findingsPeople with PD initiated BZDR use more frequently than the comparison people (39.0% vs. 25.9%). The incidence rate was higher in the PD group throughout the study period, and the incidence began to increase 2 years before and peaked at 6 months before the diagnosis.
conclusionThe higher incidence of BZDR use in persons with PD already before the PD diagnosis may indicate non-motor symptoms before the PD diagnosis. The use of fall-risk increasing BZDR for people with PD is concerning, as the disease itself increases the risk of falling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.